From what I can see their testing services are growing well and their acquistion of Invivo looks good also. I take the point that the revenue is hard to decipher which isn't good from a transperancy point of view. Their FY24 annual report should offer some clarity although it would be good if they provided these numbers in the quarterly report so investors didnt need to try to work out which division is performing and which is not.
Ann: Completion of Autoimmune Program with Ginkgo Bioworks, page-10
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MAP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
18.5¢ |
Change
0.005(2.78%) |
Mkt cap ! $82.85M | |||
| Open | High | Low | Value | Volume |
| 18.5¢ | 18.5¢ | 18.5¢ | $520 | 2.811K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 25000 | 18.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 18.5¢ | 40589 | 2 |
View Market Depth
| Last trade - 10.04am 07/10/2024 (20 minute delay) ? |
| MAP (ASX) Chart |